Skip to content
FIND A HEALTH VALLEY ACTOR

AB2 Bio & Nippon Shinyaku Partner on U.S. License for Tadekinig Alfa

AB2Bio

AB2 Bio and Nippon Shinyaku Sign U.S. Licensing Agreement for Tadekinig Alfa to Treat Ultra-Rare Autoimmune Disease   AB2 Bio Ltd., a Vaud-based biotech company specializing in therapies for severe hyperinflammatory diseases, has entered into a strategic agreement with Nippon Shinyaku, a leading Japanese pharmaceutical company, for the commercialization of its breakthrough treatment Tadekinig alfa…

Read More

Survey: Ready for the Sustainable Transition?

Enquete Durabilité

Our partner, CleantechAlps, in collaboration with regional economic players, wants to better understand your challenges and needs to develop tailored solutions for sustainable transition. We thank you for answering the survey.   With the arrival of ESG reporting, these new regulations will soon impact the entire economic landscape. By participating in this survey, you have…

Read More

Biopôle Discovery Day

Biopole Discovery Day 2026

Biopôle Discovery Day is taking place on 31 March 2026   This annual event is tailored for master’s and PhD students, young professionals and academic researchers aspiring to make their mark in the life sciences. Whether you’re a professional seeking insights from industry leaders, a student with a passion for science, or an academic looking…

Read More

Geneva to Launch AI Hub for Healthcare and Neuromodulation

Campus Biotech AI Hub

The University Hospitals of Geneva (HUG), the Department of Health and Mobilities (DSM) of the Canton of Geneva, and the Wyss Center for Bio and Neuro Engineering have signed a three-party agreement to establish an AI reference hub focused on healthcare and neuromodulation. Set to launch in late 2025, this initiative aims to enhance the…

Read More

Oculis Announce a $100 Million Capital Increase

Oculis

Swiss-Icelandic ophthalmic laboratory Oculis announced a $100 million capital increase on Friday. The financial operation was carried out through an oversubscribed offering of 5 million shares at $20 each.     Born in 2017 in Iceland, the company then expanded to the EPFL Innovation Park before setting up its headquarters in Zug. It has offices…

Read More

Wyss Center licenses Epios® to BrainScape Medical

BrainScape

The Wyss Center for Bio and Neuro Engineering announced a strategic partnership with BrainScape Medical, a newly formed company specializing in long-term brain monitoring and neurostimulation. This collaboration marks a major step forward in translating innovative neurotechnologies into real clinical solutions.   The Wyss Center  in Geneva has granted BrainScape Medical an exclusive license for…

Read More

Launch of the Deep Tech Nation Information Platform

Deep Tech Nation Switzerland

The Deep Tech Nation Switzerland Foundation (DTN) and the Startupticker Foundation have launched the Deep Tech Nation Information Platform to help venture capitalists (VCs) and institutional investors navigate Switzerland’s deep tech ecosystem.     The platform enhances access to information, promotes investment in Swiss deep tech start-ups, and aims to strengthen Switzerland’s position as a…

Read More

Biped Robotics Supported By FIT With a Digital Growth Loan

Biped Robotics

Biped Robotics develops NOA, a harness to improve mobility for visually impaired people.   The number of people with impaired vision is rising steadily, and now stands at 300 million worldwide, including 6 million blind people. For them, getting around independently is a daily challenge. Biped Robotics’ solution to this is NOA, a shoulder-worn harness…

Read More

Lemna Bio awarded a CHF 100’000 EPFL Innogrant

Lemna Bio

Lemna Bio – an EPFL startup hosted by Professor Dal Pararo’s Laboratory of Biomolecular Modeling – has been awarded a CHF 100,000 Innogrant by the jury at the EPFL Startup Launchpad.     With ageing populations and chronic diseases on the rise, the demand for effective medicines and therapies has never been greater. Yet, for decades, drug development has…

Read More

EBAMed raised EUR 1.6 Million

EBAmed

The Geneva-based company has just secured a further EUR 1.6 Million from CDP Venture Capital and the European Union. This brings the total amount raised in the series A financing round to EUR 16 Million.   EBAMed, is a Geneva-Based start-up developing a guidance system for the non-invasive treatment of heart arrhythmias through Proton Therapy.…

Read More